PharmaEssentia Corporation is a fully integrated global biopharmaceutical company headquartered in Taipei, Taiwan, advancing innovative therapies for hematology, oncology, and immunology. Founded in 2003 by scientists with extensive experience in the U.S. biotechnology industry, PharmaEssentia has evolved into a global commercial-stage biopharmaceutical company with operations across the United States, Canada, Europe, Japan, China, South Korea, Singapore, Hong Kong, and Taiwan, supported by end-to-end capabilities spanning discovery, clinical development, manufacturing, and commercialization.

PharmaEssentia has established a leadership position in myeloproliferative neoplasms (MPNs), a group of rare blood cancers, through its flagship product, BESREMi^® (ropeginterferon alfa-2b). Developed using the company’s proprietary PEGylation platform, BESREMi^® is a novel, long-acting pegylated interferon designed to provide favorable pharmacokinetic properties, enhanced tolerability, convenient biweekly dosing, and deep, durable hematologic and molecular responses. The product is approved in more than 50 countries for the treatment of adults with polycythemia vera (PV), including the United States, the European Union, Japan, China, South Korea, Taiwan, Hong Kong, and Canada. BESREMi^® is also the only interferon listed as a preferred first-line treatment for both low-risk and high-risk PV in the NCCN Clinical Practice Guidelines.

Beyond BESREMi^®, PharmaEssentia continues to strengthen its innovation portfolio through strategic licensing, acquisitions, and business development initiatives. The company is investing in next-generation therapeutic modalities, including PEG-cytokines, antibody-drug conjugates (ADCs), bispecific antibodies, cell therapies, and other precision oncology technologies. The PharmaEssentia Innovation Research Center (PIRC) in the Boston area serves as the company’s global innovation hub, accelerating the development of next-generation therapeutics through collaborations with leading academic institutions and biotechnology partners.

Building on its success in PV, PharmaEssentia is expanding the clinical and commercial potential of BESREMi^® across additional MPN indications. In the global Phase 3 SURPASS-ET study, BESREMi^® demonstrated superior efficacy compared with the control arm in terms of durable clinical response while achieving meaningful reductions in disease-associated mutation burden, supporting its potential as a disease-modifying therapy for essential thrombocythemia (ET). In 2026, Taiwan became the first country in the world to approve BESREMi^® for the treatment of ET, with regulatory reviews underway in the United States, Japan, China, and South Korea. The company is also advancing a global Phase 3 clinical program in early primary myelofibrosis (PMF) and exploring additional applications of ropeginterferon alfa-2b in hematologic malignancies.

Supporting its long-term growth strategy, PharmaEssentia operates a state-of-the-art cGMP biologics manufacturing facility in Taichung and is expanding manufacturing capacity through new facilities in Hsinchu and Puerto Rico to diversify its manufacturing footprint and strengthen supply resilience. Guided by its patient-centric mission, PharmaEssentia continues to expand its global presence and deliver innovative therapies to address significant unmet medical needs worldwide.